Any current/future new fundraising through debt or equity?

The company plans a capex of around Rs. 30 crore for the current financial year (FY20). Funding for this capex will be through a mix of debt and internal accruals. Approximately 75% of the funding is expected to come from debt, and 25% from internal accruals. The consolidated debt is anticipated to reach around Rs. 150 crore this year. There is no specific mention of new equity fundraising in the provided information. The focus appears to be on maintaining a balance between debt and internal funds to support growth and expansion plans.

Any current/future capex/capital investment/strategic investment?

Current FY20 capex plan is around Rs. 30 crore, which includes both debottlenecking and maintenance. Last year, Rs. 28 crore capex was done to help debottleneck plant processes and increase capacity by approximately 25-30%. An ongoing client-specific capex project (fine chemicals/pharmaceutical intermediates) is underway, with initial civil works partly completed; full project starting early 2020. The new Dhule facility investment is in progress, with civil work partly done; expected to start operations in Q1 of next year and further expand new business opportunities. Future capex is expected

Future growth expectations in sales/revenue/volumes?

The company targets around 20% growth in sales/revenue for the current and coming years. Volume growth is expected around 25-30%, contributing significantly to overall sales growth. Export sales aim to cross over 50-55% of total sales, with efforts to increase the number of countries served from about 50 to 70. The company focuses on both fine chemicals and specialty chemicals segments, investing and balancing sales growth in both. Market conditions are generally positive, though global volatility (e.g., US-China tensions) is monitored. Capacity utilization was around 60% in the last quarter,

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth expected around 20% for FY20, continuing strong upward trend (Page 13). Profit growth projected between 20-30% for FY20, aligned with revenue growth (Page 13). EPS improvement expected alongside revenue and profit growth; EPS rose from 4 to 7.4 in recent years (Page 17). EBITDA margins targeted to improve to 12-13% with operational efficiencies and product mix optimization (Page 12). Market conditions and global volatility recognized but optimism remains for sustained growth in exports and domestic sales (Pages 10, 12, 16). Capex of ~Rs.30 crore planned annually to exp

Current/ Expected Orderbook/ Pending Orders?

The company is targeting a reasonably high order book growth, aiming for a 20% upside in the near term. In the last quarter, the indication was for an order book close to Rs. 125 crore to Rs. 150 crore for Q4. The company cannot give a direct order book number but affirms a 20% upside is possible. They expect the new Dhule facility to start in the first quarter of the next year, which may impact pending orders and capacity. Overall, the order book outlook is positive with growth expectations around 20%.

IN US

Sale is live|00:00:00left today

Indo Amines LtdQ1 FY19Chemicals & Petrochemicals

Indo Amines Ltd Q1 FY19 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹138P/E: 13.1Market Cap: ₹925 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company targets around 20% growth in sales/revenue for the current and coming years.
→Volume growth is expected around 25-30%, contributing significantly to overall sales growth.
→Export sales aim to cross over 50-55% of total sales, with efforts to increase the number of countries served from about 50 to 70.
→The company focuses on both fine chemicals and specialty chemicals segments, investing and balancing sales growth in both.
→Market conditions are generally positive, though global volatility (e.g., US-China tensions) is monitored.
→Capacity utilization was around 60% in the last quarter, with plans for new facility expansions, such as the Dhule facility opening next year.
→Continuous investment in capacity and operations is planned, with approximately Rs. 30 crore capex yearly to support growth.
→The company is aggressively increasing market share within existing and new markets.

Margin guidance

Category 2

→Revenue growth expected around 20% for FY20, continuing strong upward trend (Page 13).
→Profit growth projected between 20-30% for FY20, aligned with revenue growth (Page 13).
→EPS improvement expected alongside revenue and profit growth; EPS rose from 4 to 7.4 in recent years (Page 17).
→EBITDA margins targeted to improve to 12-13% with operational efficiencies and product mix optimization (Page 12).
→Market conditions and global volatility recognized but optimism remains for sustained growth in exports and domestic sales (Pages 10, 12, 16).
→Capex of ~Rs.30 crore planned annually to expand capacity, supporting top-line and margin growth (Pages 15, 16).
→Company aims for sustainable expansion by increasing market share and launching new products (Pages 10, 17).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company plans a capex of around Rs. 30 crore for the current financial year (FY20).
→Funding for this capex will be through a mix of debt and internal accruals.
→Approximately 75% of the funding is expected to come from debt, and 25% from internal accruals.
→The consolidated debt is anticipated to reach around Rs. 150 crore this year.
→There is no specific mention of new equity fundraising in the provided information.
→The focus appears to be on maintaining a balance between debt and internal funds to support growth and expansion plans.

Order book

Yes

→The company is targeting a reasonably high order book growth, aiming for a 20% upside in the near term.
→In the last quarter, the indication was for an order book close to Rs. 125 crore to Rs. 150 crore for Q4.
→The company cannot give a direct order book number but affirms a 20% upside is possible.
→They expect the new Dhule facility to start in the first quarter of the next year, which may impact pending orders and capacity.
→Overall, the order book outlook is positive with growth expectations around 20%.

Capex plans

Yes

→Current FY20 capex plan is around Rs. 30 crore, which includes both debottlenecking and maintenance.
→Last year, Rs. 28 crore capex was done to help debottleneck plant processes and increase capacity by approximately 25-30%.
→An ongoing client-specific capex project (fine chemicals/pharmaceutical intermediates) is underway, with initial civil works partly completed; full project starting early 2020.
→The new Dhule facility investment is in progress, with civil work partly done; expected to start operations in Q1 of next year and further expand new business opportunities.
→Future capex is expected to continue roughly at Rs. 30 crore annually to support growth and capacity expansions.
→Funding for the capex will be through a mix of debt (approx. 75%) and internal accruals (approx. 25%).

How does Indo Amines Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Indo Amines Ltd

Rev 2Mar 2

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Indo Amines Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio